Ndovu RCT: Investing the Optimal Management of Dolutegravir Resistance

PHASE3RecruitingINTERVENTIONAL
Enrollment

392

Participants

Timeline

Start Date

September 1, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

July 31, 2027

Conditions
HIV-1-infection
Interventions
DRUG

Dolutegravir Pill

Dose will be based on weight; brand names will be as supplied through the respective national programs

DRUG

Darunavir+Ritonavir

Dose will be based on weight

Trial Locations (9)

Unknown

RECRUITING

Jaramogi Oginga Odinga Teaching and Referral Hospital, Kisumu

NOT_YET_RECRUITING

Bomu Hospital, Mombasa

NOT_YET_RECRUITING

Butha-Buthe District Hospital, Butha-Buthe

NOT_YET_RECRUITING

Mokhotlong District Hospital, Mokhotlong

NOT_YET_RECRUITING

CS Ponta Gea, Beira

NOT_YET_RECRUITING

CS Machava II, Maputo

NOT_YET_RECRUITING

CS Ndlavela, Maputo

NOT_YET_RECRUITING

MUHAS Clinical Trial Unit, Dar es Salaam

00100

RECRUITING

Kenyatta National Hospital, Nairobi

All Listed Sponsors
collaborator

Instituto Nacional de Saúde, Mozambique

OTHER_GOV

collaborator

Muhimbili University of Health and Allied Sciences

OTHER

collaborator

SolidarMed

OTHER

collaborator

London School of Hygiene and Tropical Medicine

OTHER

lead

University of Nairobi

OTHER

NCT06747507 - Ndovu RCT: Investing the Optimal Management of Dolutegravir Resistance | Biotech Hunter | Biotech Hunter